Your session is about to expire
← Back to Search
Palbociclib Combination Therapy for Refractory Leukemia
Study Summary
This trial is testing the side effects and best dose of the drug palbociclib, given alone and with other drugs, to treat patients with leukemia that has returned or does not respond to previous treatment.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2023 Phase 2 trial • 55 Patients • NCT03007979Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I haven't received leukemia treatment in the last 14 days, except possibly hydroxyurea.I understand the study's requirements and have signed the consent form.I do not have active, uncontrolled leukemia in my brain or spinal cord.I am using contraception or agree to start using it during the study.I do not have any severe illnesses that could interfere with the study.I understand the study's requirements and have signed the consent form.My leukemia has returned or didn't respond to treatment, and no standard treatments are expected to work.I haven't had leukemia treatment in the last 14 days, but I may have taken hydroxyurea.I do not have a history of serous retinopathy.I have been treated with palbociclib before.I am not pregnant or breastfeeding.I can take care of myself but might not be able to do heavy physical work.I have relapsed or refractory acute lymphoblastic leukemia.My leukemia has returned or didn't respond to treatment, and no standard treatments are expected to work.I have relapsed or refractory acute lymphoblastic leukemia.I can take care of myself but might not be able to do heavy physical work.
- Group 1: Arm III (palbociclib, dexamethasone)
- Group 2: Arm I (palbociclib, sorafenib)
- Group 3: Arm II (palbociclib, decitabine)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there any available slots for participation in this research study?
"The clinical trial's progress can be tracked on clinicaltrials.gov; the study was initially advertised on July 25th 2017 and most recently updated June 29th 2022, indicating that it is actively searching for participants."
What related investigations have been done concerning Palbociclib?
"Currently, 838 Palbociclib trials are underway with 196 of them in the advanced Phase 3. Joliet, Illinois is a hub for research on this medication yet there are 29250 locations conducting clinical experiments involving Palbociclib across the globe."
What potential hazards does Palbociclib present to individuals?
"Due to its Phase 1 status, Palbociclib has only been granted a score of 1 in terms of safety by the Power team since there is relatively limited clinical data available on efficacy and safety."
How many participants have been enlisted for this medical research?
"Correct. The clinicaltrials.gov webpage confirms that the trial, which was first published on July 25th 2017, is still actively recruiting patients across one medical centre with a sample size of 54 individuals."
What medical conditions can Palbociclib be used to address?
"Palbociclib is effective at treating ophthalmia, sympathetic eye conditions, branch retinal vein occlusions and macular edema."
Share this study with friends
Copy Link
Messenger